SCTbio and Cyto-care Collaborate to Improve Cell Therapy Cryopreservation
The companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.
SCTbio, a contract development and manufacturing organization (CDMO), and Cyto-care.eu GmbH, a company that specializes in providing advanced solutions for cell therapy and regenerative medicine, have both signed a collaboration agreement to improve the quality of cryopreservation for cell therapy development in Europe. With this collaboration, the companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow, according to the press release.
A major step for manufacturing advanced cell therapies products (ATMPs) is through the use of cell collection through leukapheresis procedure. Further, the quantity and quality of collected immune cells can directly impact the potency, safety, and efficacy of the final therapeutic product. For this specific collaboration, SCTbio and Cyto-care.eu want to provide a reliable, accessible platform for collecting, characterizing, preserving, and transporting leukapheresis samples.
“We are thrilled to combine both forces and expertise with Cyto-care.eu, a European leader in producing quality blood-based products from leukapheresis, through this strategic partnership,” said Luděk Sojka, CEO of SCTbio, in a press release. “As the cell and gene therapy field continues to advance, the demand for leukapheresis materials is expected to increase. Clinical trials and commercial production of these therapies require a consistent and reliable supply of high-quality blood-derived products to meet patient needs.”
“Through rigorous analysis and in-depth discussions with the experts of the field, the Needle-to-Freezing time has been identified as a crucial factor for success for the development and manufacturing of ATMPs,” said Klaus Fischer, Cyto-care.eu’s managing director, in a press release. “Through this collaboration with SCTbio, we can ensure that our leukapheresis products from patients and from donors continue to meet the high-quality standards of our customers’ requirements.”
Source: SCTbio
